264 related articles for article (PubMed ID: 18550081)
21. [Infliximab treatment trial in a patient with neuro-Behçet's disease unresponsive to other treatments].
Kadowaki S; Matsuda N; Moriya A; Ebitani M; Yoshihara A; Nakamura K; Mochizuki H; Ugawa Y
Rinsho Shinkeigaku; 2011 Apr; 51(4):261-6. PubMed ID: 21595295
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of severe Behçet's disease with anti-TNF-alpha: infliximab. A case report].
Andreu M; Ramanoelina J; Fajnkuchen F; Mouthon L; Cohen P; Laroche L; Guillevin L
Ann Med Interne (Paris); 2002 Oct; 153(6):414-5. PubMed ID: 12486393
[No Abstract] [Full Text] [Related]
23. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
[TBL] [Abstract][Full Text] [Related]
24. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
25. Magnetic resonance imaging findings and outcome of neuro-Behçet's disease: the predictive factors.
Farahangiz S; Sarhadi S; Safari A; Borhani-Haghighi A
Int J Rheum Dis; 2012 Dec; 15(6):e142-9. PubMed ID: 23253242
[TBL] [Abstract][Full Text] [Related]
26. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
Sarwar H; McGrath H; Espinoza LR
J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome.
Akman-Demir G; Tüzün E; Içöz S; Yeşilot N; Yentür SP; Kürtüncü M; Mutlu M; Saruhan-Direskeneli G
Cytokine; 2008 Dec; 44(3):373-6. PubMed ID: 19010690
[TBL] [Abstract][Full Text] [Related]
29. Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis.
Adler S; Baumgartner I; Villiger PM
Arthritis Care Res (Hoboken); 2012 Apr; 64(4):607-11. PubMed ID: 22162223
[TBL] [Abstract][Full Text] [Related]
30. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
Ainsworth MA; Bendtzen K; Brynskov J
Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
Jalili A; Kinaciyan T; Barisani T; Peck-Radosavljevic M; Stingl G; Geusau A; Wöhrl S
Iran J Immunol; 2009 Mar; 6(1):55-8. PubMed ID: 19293479
[No Abstract] [Full Text] [Related]
33. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
[TBL] [Abstract][Full Text] [Related]
34. Levels of IL-15 in serum and cerebrospinal fluid of patients with Behçet's disease.
Hamzaoui K; Hamzaoui A; Ghorbel I; Khanfir M; Houman H
Scand J Immunol; 2006 Dec; 64(6):655-60. PubMed ID: 17083622
[TBL] [Abstract][Full Text] [Related]
35. Infliximab in refractory uveitis due to Behçet's disease.
Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
[TBL] [Abstract][Full Text] [Related]
36. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
[No Abstract] [Full Text] [Related]
37. [Chronic Progressive Neuro-Behçet's Disease].
Hirohata S
Brain Nerve; 2021 May; 73(5):568-575. PubMed ID: 34006690
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report.
Borhani Haghighi A; Safari A
Clin Neurol Neurosurg; 2008 Mar; 110(3):315-6. PubMed ID: 18053588
[No Abstract] [Full Text] [Related]
39. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease.
Hirohata S; Suda H; Hashimoto T
J Neurol Sci; 1998 Aug; 159(2):181-5. PubMed ID: 9741405
[TBL] [Abstract][Full Text] [Related]
40. The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells.
Musacchio E; Valvason C; Botsios C; Ostuni F; Furlan A; Ramonda R; Modesti V; Sartori L; Punzi L
J Rheumatol; 2009 Aug; 36(8):1575-9. PubMed ID: 19567627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
